Repligen Corporation
$ 163.90
2.80%
07 Aug - close price
- Market Cap 9,249,798,000 USD
- Current Price $ 163.90
- High / Low $ 164.97 / 159.44
- Stock P/E 224.52
- Book Value 37.43
- EPS 0.73
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.02 %
- 52 Week High 175.77
- 52 Week Low 100.99
About
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$185.70
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-28 | 2026-05-05 | 2026-02-24 | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-20 | 2024-11-12 | 2024-07-30 | 2024-05-01 | 2024-02-21 | 2023-10-31 |
| Reported EPS | 0.54 | 0.48 | 0.49 | 0.46 | 0.37 | 0.39 | 0.44 | -0.0117 | 0.33 | 0.28 | 0.33 | 0.23 |
| Estimated EPS | 0.45 | 0.39 | 0.4394 | 0.41 | 0.39 | 0.35 | 0.4191 | 0.33 | 0.33 | 0.3 | 0.33 | 0.16 |
| Surprise | 0.09 | 0.09 | 0.0506 | 0.05 | -0.02 | 0.04 | 0.0209 | -0.3417 | 0 | -0.02 | 0 | 0.07 |
| Surprise Percentage | 20% | 23.0769% | 11.5157% | 12.1951% | -5.1282% | 11.4286% | 4.9869% | -103.5455% | 0% | -6.6667% | 0% | 43.75% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGEN
2026-08-04 10:09:12
Repligen Corporation has announced an agreement to acquire BioLife Solutions for a combination of cash and stock. BioLife shareholders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share. The transaction, described as a strategic combination in the cell therapy market, is anticipated to close in the fourth quarter of 2026, pending regulatory and BioLife stockholder approvals.
2026-08-03 21:10:23
BioLife Solutions (NASDAQ: BLFS) has informed its employees about its pending merger with Repligen Corporation, distributing an internal email with a video from Repligen's CEO. The video introduces Repligen and discusses the anticipated benefits of the combination, particularly growth opportunities in the cell therapy market. The merger is subject to regulatory clearances and BioLife stockholder approval and is expected to close in the fourth quarter of the current year.
2026-08-03 05:10:23
This article analyzes Repligen Corporation (RGEN) using AI models to offer trading strategies. It highlights a strong near-term sentiment with a neutral mid- and long-term outlook, identifying an exceptional risk-reward setup. The analysis provides specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies.
2026-08-02 05:11:20
Repligen (RGEN) stock increased by 6.9% despite mixed Q2 2026 results which showed higher revenue but lower EPS. The company reported revenue of US$204.13 million, up from US$182.37 million year-over-year, but net income and diluted EPS declined. Analysts have revised earnings estimates higher, maintaining a positive long-term view despite near-term margin pressure and recent index removals impacting sentiment.
2026-08-01 09:10:21
Repligen Corporation (RGEN) reported mixed Q2 2026 results, with revenue increasing to US$204.13 million from US$182.37 million year-over-year, but net income and diluted EPS falling to US$5.01 million and US$0.09 respectively. Despite the decline in profitability, analysts have raised earnings estimates and maintained a positive outlook on the company's long-term earnings potential, leading to a 6.9% stock price increase. The article discusses how these results and recent index removals affect the investment narrative, emphasizing the importance of monitoring profit margin recovery.
2026-08-01 08:10:21
Repligen Corp (RGEN) has an institutional confidence score of 10.00, placing it first in its industry. Institutional shareholding increased by 3.23% quarter-over-quarter, with Lee Ainslie being the largest shareholder. The article lists the top institutional shareholders and their recent activity.
